Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

New prognostic markers in chronic lymphocytic leukemia

(2008) Carol Moreno et al.   BLOOD REVIEWS

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

(2008) F. Bosch et al.   CLINICAL CANCER RESEARCH

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY

Variations on the Fludarabine, Cyclophosphamide, and Rituximab Combination in Chronic Lymphocytic Leukemia Therapy: What Have We Learned?

(2008) Tahamtan Ahmadi et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses

(2008) Nicole Lamanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2008) Kenneth A. Foon et al.   JOURNAL OF CLINICAL ONCOLOGY